Not Yet Recruiting
Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
NCT07231250
- Conditions
- Bispecific Antibody, Chemo-free Therapy, DLBCL - Diffuse Large B Cell Lymphoma, +7 more
- Locations
-
- Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China